Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure

American Heart Journal

Volumn 145, Issue 5, 2003, Pages 926-932

  Rouleau, Jean L ^a,f   Pitt, B ^b   Dhalla, N S ^c   Dhalla, K S ^c   Swedberg, K ^d   Hansen, M S ^a   Stanton, E ^a   Lapointe, N ^a   Packer, M ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOLUTIN;

ADULT; AGED; ARTICLE; CATECHOLAMINE RELEASE; CELL DEATH; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL;

EID: 0038065613     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)94782-4     Document Type: Article

References (25)

1. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. Rupp H, Dhalla KS, Dhalla DS. Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994;24(1 Suppl):S16-24.
3. Dhalla NS, Sasaki H, Mochzuki S, et al. Catecolamine-induced cardiomyopathy. In: Acosta D Jr, editor. Cardiovascular toxicology. 3rd edition. New York: Taylor and Francis; 2001. p. 269-317.
4. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(6 Suppl):140-8.
5. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-73.
6. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
7. Palace VP, Hill MF, Farahmand F, et al. Mobilization of antioxidant vitamin pools and hemodynamic function after myocardial infarction. Circ Res 1999;99:121-6.
8. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-14.
9. Kinugawa S, Tsutsui H, Hayashidani S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000;87:392-8.
10. Dhalla KS, Ganguly PK, Rupp H, et al. Measurement of adrenolutin as an oxidation product of catecholamines in plasma. Mol Cell Biochem 1989;87:85-92.
11. Kukreja RC, Hess ML. The oxygen free radical system: from equations to membrane-protein interactions to cardiovascular injury and protection. Cardiovasc Res 1992;26:641-55.
12. Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunctian and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981;102:210-21.
13. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001;134:550-60.
14. Prabhu SD, Chandrasekar B, Myrray DR, et al. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-9.
15. Beanlands RSB, Nahmias C, Gordon E, et al. The effects of beta-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction. Circulation 2000;102:2070-5.
16. Flesch M, Maack C, Cremers B, et al. The effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999;100:346-53.
17. Sabbah HN, Sharov VG, Gupta RC, et al. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 2000;36:1698-705.
18. Yates JC, Taam GML, Singal PK, et al. Protection against adrenochrome-induced myocardial damage by various pharmacological interventions. Br J Exp Pathol 1980;61:242-55.
19. Packer M, Rouleau JL, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation 1993;88(1 Suppl):1-301.
20. Moe GW, Rouleau JL, Charbonneau L, et al. Neurohumoral activation by flosequinan contributes to increased mortality in patients with severe heart failure. Am Heart J 2000;139:587-95.
21. Mann DL. Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive. Prog Cardiovasc Dis 1998;41 (1 Suppl):1-8.
22. Bindoli A, Rigobelleo MP, Galzigna L. Toxicity of aminochromes. Toxicol Lett 1989;48:3-20.
23. Levine B, Kalman J, Mager L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:136-41.
24. Chen L, Zang Y, Bai B, et al. Electron spin resonance determination and superoxide dismutase activity in polymorphonuclear leucocytes in congestive heart failure. Can J Cardiol 1992;8:756-60.
25. Rockman HA, Juneau C, Chatterjee K, et al. Predictors of sudden death and low output death in chronic congestive heart failure: importance of plasma renin activity. Am J Cardiol 1989;64:1343-8.